SCHEMBL4450020

SCHEMBL4450020

COC(=O)CNC1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL76321 0.98 EPHX2 (0.47)
SCHEMBL13450036 0.92 EPHX2 (0.43)
SCHEMBL23165799 0.92 EPHX2 (0.43)
SCHEMBL23165798 0.92 EPHX2 (0.43)
SCHEMBL1977433 0.91 EPHX2 (0.59)
SCHEMBL7440501 0.91 EPHX2 (0.55)
SCHEMBL16374968 0.90 SMYD3 (0.43)
SCHEMBL18845118 0.89 EPHX2 (0.62)
SCHEMBL2411177 0.89 EPHX2 (0.62)
Hydrochloric Acid SCHEMBL6871695 0.89 EPHX2 (0.58)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240158412-A1 UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF FAXIAN THERAPEUTICS, LLC 2024-05-16 US disclosed
EP-4288442-A1 UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF Faxian Therapeutics, LLC (US) 2023-12-13 EP disclosed
CN-116332910-A 2-aminopyrimidine derivatives as kinase inhibitors, preparation and use thereof 江苏威凯尔医药科技有限公司 2023-06-27 CN disclosed
WO-2022170198-A1 UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF FAXIAN THERAPEUTICS, LLC (US) 2022-08-11 WO disclosed
US-10258602-B2 Macrocyclic ghrelin receptor modulators and methods of using the same OCERA THERAPEUTICS, INC. (US) 2019-04-16 US disclosed
US-9949949-B2 Macrocyclic ghrelin receptor modulators and methods of using the same OCERA THERAPEUTICS, INC. (US) 2018-04-24 US disclosed
US-20170042858-A1 MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY 2017-02-16 US disclosed
EP-2118080-B1 MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME OCERA THERAPEUTICS INC (US) 2016-08-31 EP disclosed
EP-2644618-B1 tether intermediates for the synthesis of macrocyclic ghrelin receptor modulators OCERA THERAPEUTICS INC (US) 2016-08-17 EP disclosed
WO-2016106625-A1 BTK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-07-07 WO disclosed
CN-101657436-A macrocyclic ghrelin receptor modulators and methods of use thereof TRANZYME PHARMA INC US 2010-02-24 CN disclosed
EP-2118080-A1 MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME Tranzyme Pharma, Inc. (US) 2009-11-18 EP disclosed
WO-2008130464-A1 MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME TRANZYME PHARMA, INC. (US) 2008-10-30 WO disclosed
US-20080194672-A1 MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME TRANZYME PHARMA INC. 2008-08-14 US disclosed
US-7300934-B2 Benzamide nitriles ROCHE PALO ALTO LLC (US) 2007-11-27 US disclosed
CN-1798729-A Benzamide nitrile derivatives HOFFMANN LA ROCHE (CH) 2006-07-05 CN disclosed
EP-1633701-A1 BENZAMIDE NITRILE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2006-03-15 EP disclosed
WO-2004106285-A1 BENZAMIDE NITRILE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-12-09 WO disclosed
US-20040248949-A1 Benzamide nitriles ROCHE PALO ALTO LLC 2004-12-09 US disclosed
US-4005208-A GASTRIC JUICE, ANTISECRETORY SMITHKLINE CORPORATION (US) 1977-01-25 US disclosed